We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Bioequivalence Study Between Two Oral Formulations of Gemfibrozil Tablets

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: December 2, 2008
Last Update Posted: August 13, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Blu Caribe
The purpose of this study is to determine whether two oral formulations of Gemfibrozil Tablets are bioequivalent.

Condition Intervention Phase
Bioavailability Drug: Gemfibrozil Tablets Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Relative Bioequivalence Study of 600 mg Gemfibrozil Tablets Under Fasting Conditions

Resource links provided by NLM:

Further study details as provided by Blu Caribe:

Primary Outcome Measures:
  • Bioequivalence was assessed on the pharmacokinetic variables, Cmax, AUCO-t and AUCO-infinity

Enrollment: 40
Study Start Date: July 2005
Study Completion Date: September 2005
Primary Completion Date: July 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Test Drug Drug: Gemfibrozil Tablets
Active Comparator: Reference Drug Drug: Gemfibrozil Tablets


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • healthy men or women 18 years of age or older
  • weight within +/- 20% for height and body frame
  • willing to participate and sign a copy of the informed consent form

Exclusion Criteria:

  • recent history of drug or alcohol addiction or abuse
  • pregnant or lactating women
  • history of allergic response to gemfibrozil
  • use of tobacco products
  • evidence of a clinically significant disorder or whose laboratory results were deemed to be clinically significant
  • receipt of any drugs as part of a research study within 28 days prior to study dosing
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Blu Caribe
ClinicalTrials.gov Identifier: NCT00800475     History of Changes
Other Study ID Numbers: R05-0116
First Submitted: November 26, 2008
First Posted: December 2, 2008
Last Update Posted: August 13, 2013
Last Verified: August 2013

Keywords provided by Blu Caribe:

Additional relevant MeSH terms:
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Cytochrome P-450 CYP2C8 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors